FI105548B - Förfarande för framställning av farmaceutiskt aktiva 1,3-dihydro-2H-imidazo(4,5-b)kinolin-2-oner - Google Patents
Förfarande för framställning av farmaceutiskt aktiva 1,3-dihydro-2H-imidazo(4,5-b)kinolin-2-oner Download PDFInfo
- Publication number
- FI105548B FI105548B FI942010A FI942010A FI105548B FI 105548 B FI105548 B FI 105548B FI 942010 A FI942010 A FI 942010A FI 942010 A FI942010 A FI 942010A FI 105548 B FI105548 B FI 105548B
- Authority
- FI
- Finland
- Prior art keywords
- formula
- alkyl
- optionally substituted
- dihydro
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (8)
1. Förfarande för framställning av farmaceutiskt aktiva 1,3-dihydro-2H-imidazo[4,5-b]kinolin-2-oner med 5 formeln (I), farmaceutiskt godtagbara additionssalter därav eller stereokemiska isomerformer därav, X t (I c H V ' iXx väri R är väte, fenyl, som valfritt är substituerad med 15 1-3 substituenter, vilka envar självständigt är valda bland halogen, C^-alkyloxi och C1.6-alkyl; eller R är pyridinyl; X C=X är en radikal med formeln 20 I^C=0 (a) eller X:c=N-0-R1 (b) ; R1 är C^.g-alkyl valfritt substituerad med COOH, COOC-^-alkyl eller CONR3R4, ” 25 R3 är C^-alkyl; R4 är C3.7-cykloalkyl; eller R3 och R4 kan tillsammans med kväveatomen, vid vil-ken de är bundna, bilda en piperazinylring, varvid piperazinylringen valfritt i kväveatomen är substituerad 30 med C1.4-alkyl eller (C3_7-cykloalkyl) -C^-alkyl ; * kännetecknat därav, att man a) cykliserar en mellanprodukt med formeln X 35 'ij> * €Q> NH2 o H 32 105548 väri R och C=X är säsom ovan def inierats, i ett lös-ningsmedel i närvaro av en syra; b) cykliserar en mellanprodukt med formeln l (III) * 1CQ>0 nh2 O h 10 väri R och ^ C=X är säsom ovan definierats, i ett lös-ningsmedel i närvaro av en syra; c) omvandlar föreningarna med formeln (I) tili varandra genom esterhydrolys; och om önskvärt, omvandlar föreningarna med formeln (I) 15 tili saltform genom behandling med en farmaceutiskt god-tagbar syra eller bas, eller omvänt, omvandlar saltformen tili en fri bas eller en fri syra genom behandling med alkali, respektive syra; och/eller framställer stereo-kemiska isomerformer därav. 20
2. Förfarande enligt patentkrav 1, känne- t e c k n a t därav, att R är väte; fenyl, som valfritt är substituerad med 1 eller 2 substituenter, vilka envar självständigt är valda bland halogen, C^-alkyloxi eller Cj.g-alkyl; eller R är pyridinyl. 25
3. Förfarande enligt patentkrav 2, känne- t e c k n a t därav, att R är väte; fenyl, som valfritt är substituerad med 1 eller 2 substituenter, vilka envar självständigt är valda bland fluor, klor, brom, metoxi eller metyl; eller R är pyridinyl; och C=X är en 30 radikal med formeln (a) eller (b) , väri R1 är C^-alkyl, ! som valfritt är substituerad med COOH, COOC^-alkyl eller CONR3R4.
4. Förfarande enligt patentkrav 3, känne- ’ t e c k n a t därav, att R är väte eller fenyl, som 35 valfritt är substituerad med 1 eller 2 substituenter, 33 105548 eller metyl, och ^C=X är en radikal med formeln (a) eller (b) ; väri R1 är C1.4-alkyl, som valfritt är substituerad med COOH, COOC2H5, CON(CH3) (c.CgH^) eller 5 5? /—\ —C-N^_^N—CH2—(cCeHu).
5. Förfarande enligt patentkrav 1, känne- t e c k n a t därav, att man framställer (E) -N-cyklo- 10 hexyl-2-[[[(2,3-dihydro-2-oxo-lH-imidazo[4,5-b]kinolin-7-yl)fenylmetylen]amino]oxi]-N-metylacetamid.
6. Förfarande enligt patentkrav 1, kanne- t e c k n a t därav, att man framställer 7-benzoyl-1,3-dihydro-2H-imidazo[4,5-b]kinolin-2-on. 15
7. Förfarande enligt patentkrav 1, känne- t e c k n a t därav, att man framställer (E) -1- (cyk-lohexylmetyl)-4-[[[[(2,3-dihydro-2-oxo-lH-imidazo[4,5-b]-kinolin-7-yl)metylen]amino]oxi]acetyl]piperazin.
8. Förfarande enligt patentkrav 1, känne-20 tecknat därav, att man framställer (E) -N-cyk-lohexyl-2-[[[(2,3-dihydro-2-oxo-lH-imidazo[4,5-b]kinolin-7-yl) metylen] amino] oxi] -IJ-nietylacetamid. ♦ *'
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78495591A | 1991-10-30 | 1991-10-30 | |
US78495591 | 1991-10-30 | ||
PCT/EP1992/002496 WO1993009118A1 (en) | 1991-10-30 | 1992-10-27 | 1,3-dihydro-2h-imidazo(4,5-b)quinolin-2-one derivatives as phosphodiesterase inhibitors |
EP9202496 | 1992-10-27 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI942010A FI942010A (sv) | 1994-04-29 |
FI942010A0 FI942010A0 (sv) | 1994-04-29 |
FI105548B true FI105548B (sv) | 2000-09-15 |
Family
ID=25134048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI942010A FI105548B (sv) | 1991-10-30 | 1994-04-29 | Förfarande för framställning av farmaceutiskt aktiva 1,3-dihydro-2H-imidazo(4,5-b)kinolin-2-oner |
Country Status (24)
Country | Link |
---|---|
US (3) | US5521187A (sv) |
EP (2) | EP0610372B1 (sv) |
JP (1) | JP3488922B2 (sv) |
KR (1) | KR100251895B1 (sv) |
CN (1) | CN1041726C (sv) |
AT (1) | ATE131479T1 (sv) |
AU (1) | AU660337B2 (sv) |
CA (1) | CA2121230C (sv) |
DE (1) | DE69206820T2 (sv) |
DK (1) | DK0610372T3 (sv) |
ES (1) | ES2083773T3 (sv) |
FI (1) | FI105548B (sv) |
GR (1) | GR3018909T3 (sv) |
HU (1) | HU220608B1 (sv) |
IL (1) | IL103570A (sv) |
MX (1) | MX9206258A (sv) |
NO (1) | NO300976B1 (sv) |
NZ (1) | NZ244779A (sv) |
PH (1) | PH31245A (sv) |
PL (1) | PL170749B1 (sv) |
RU (1) | RU2127273C1 (sv) |
TW (1) | TW249234B (sv) |
WO (1) | WO1993009118A1 (sv) |
ZA (1) | ZA928373B (sv) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
US5502177A (en) * | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5703827A (en) * | 1996-02-29 | 1997-12-30 | Monolithic System Technology, Inc. | Method and structure for generating a boosted word line voltage and a back bias voltage for a memory array |
US6028183A (en) | 1997-11-07 | 2000-02-22 | Gilead Sciences, Inc. | Pyrimidine derivatives and oligonucleotides containing same |
US6007992A (en) * | 1997-11-10 | 1999-12-28 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
HUP0302167A3 (en) * | 2000-10-02 | 2010-03-29 | Janssen Pharmaceutica Nv | Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
MXPA03010672A (es) | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Composicion para el tratamiento regenerativo de enfermedades del cartilago. |
CA2447619A1 (en) | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | A composition for accelerating bone fracture healing |
SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
JP4573533B2 (ja) * | 2002-03-29 | 2010-11-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 放射能標識付きキノリンおよびキノリノン誘導体および代謝向性グルタメート受容体リガンドとしてのそれらの使用 |
SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
BRPI0412902A (pt) | 2003-08-12 | 2006-09-26 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por oxima |
ES2406730T3 (es) | 2003-08-27 | 2013-06-07 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi |
CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
RU2412942C2 (ru) | 2003-10-03 | 2011-02-27 | 3М Инновейтив Пропертиз Компани | Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов |
AU2004291101A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
EP1682544A4 (en) | 2003-11-14 | 2009-05-06 | 3M Innovative Properties Co | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS |
MY161812A (en) | 2003-11-25 | 2017-05-15 | 3M Innovative Properties Co | Substituted imidazo ring systems and methods |
EP1701955A1 (en) | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
AU2004312508A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
WO2005090316A1 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | HYDANTOINS HAVING RNase MODULATORY ACTIVITY |
AU2005228150A1 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
AU2005326708C1 (en) | 2004-12-30 | 2012-08-30 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
US7968563B2 (en) | 2005-02-11 | 2011-06-28 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
EP1863814A1 (en) | 2005-04-01 | 2007-12-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
EP1969929A1 (de) * | 2007-03-12 | 2008-09-17 | Bayer CropScience AG | Substituierte Phenylamidine und deren Verwendung als Fungizide |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
CN104822691B (zh) | 2012-10-02 | 2018-04-10 | 加州理工学院 | 由活性硅烷对芳族的c‑o键、c‑n键和c‑s键的无过渡金属还原裂解 |
CN107253967B (zh) | 2012-10-02 | 2021-03-30 | 加州理工学院 | 芳族化合物的无过渡金属的甲硅烷基化 |
CA2955546C (en) | 2014-08-06 | 2022-12-13 | California Institute Of Technology | Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts |
EP3189063B1 (en) | 2014-09-02 | 2019-08-14 | California Institute of Technology | Base-catalyzed silylation of terminial alkyne c-h bonds |
WO2016100606A1 (en) | 2014-12-19 | 2016-06-23 | California Institute Of Technology | Silylation of aromatic heterocycles by disilanes using potassium alkoxide catalysts |
CN110441434A (zh) * | 2019-08-29 | 2019-11-12 | 重庆华邦胜凯制药有限公司 | Gc-ms分离测定对氨基水杨酸中相关杂质的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1602188A (en) * | 1977-12-01 | 1981-11-11 | Wellcome Found | Hydantoin derivatives |
JPS6021941B2 (ja) * | 1981-01-28 | 1985-05-30 | 株式会社村田製作所 | 圧電性磁器組成物 |
US4668686A (en) * | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
US4775674A (en) * | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
US4701459A (en) * | 1986-07-08 | 1987-10-20 | Bristol-Myers Company | 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation |
US5306822A (en) * | 1988-05-25 | 1994-04-26 | Warner-Lambert Company | Arylmethylenyl derivatives of oxazolidinone |
CN1030196C (zh) * | 1989-07-07 | 1995-11-01 | 詹森药业有限公司 | 增强收缩力和舒张力的-二氢咪唑并喹唑啉酮衍生物的制备方法 |
NZ234186A (en) * | 1989-07-07 | 1991-10-25 | Janssen Pharmaceutica Nv | Imidazo quinazolin-one derivatives and pharmaceutical compositions |
US5043327A (en) * | 1989-07-18 | 1991-08-27 | Janssen Pharmaceutica N.V. | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use |
US4943573A (en) * | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
WO1991007177A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders |
PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
-
1992
- 1992-10-13 PH PH45100A patent/PH31245A/en unknown
- 1992-10-16 NZ NZ244779A patent/NZ244779A/en unknown
- 1992-10-22 TW TW081108413A patent/TW249234B/zh active
- 1992-10-27 WO PCT/EP1992/002496 patent/WO1993009118A1/en active IP Right Grant
- 1992-10-27 DE DE69206820T patent/DE69206820T2/de not_active Expired - Lifetime
- 1992-10-27 EP EP92923030A patent/EP0610372B1/en not_active Expired - Lifetime
- 1992-10-27 KR KR1019940701365A patent/KR100251895B1/ko not_active IP Right Cessation
- 1992-10-27 RU RU94019971/04A patent/RU2127273C1/ru not_active IP Right Cessation
- 1992-10-27 AT AT92923030T patent/ATE131479T1/de not_active IP Right Cessation
- 1992-10-27 ES ES92923030T patent/ES2083773T3/es not_active Expired - Lifetime
- 1992-10-27 PL PL92303446A patent/PL170749B1/pl unknown
- 1992-10-27 CA CA002121230A patent/CA2121230C/en not_active Expired - Lifetime
- 1992-10-27 DK DK92923030.8T patent/DK0610372T3/da active
- 1992-10-27 JP JP50815493A patent/JP3488922B2/ja not_active Expired - Lifetime
- 1992-10-27 US US08/204,412 patent/US5521187A/en not_active Expired - Lifetime
- 1992-10-27 AU AU29083/92A patent/AU660337B2/en not_active Expired
- 1992-10-27 EP EP92203295A patent/EP0541153A1/en active Pending
- 1992-10-27 HU HU9401245A patent/HU220608B1/hu not_active IP Right Cessation
- 1992-10-28 IL IL10357092A patent/IL103570A/en not_active IP Right Cessation
- 1992-10-29 MX MX9206258A patent/MX9206258A/es unknown
- 1992-10-29 ZA ZA928373A patent/ZA928373B/xx unknown
- 1992-10-30 CN CN92112391A patent/CN1041726C/zh not_active Expired - Fee Related
-
1994
- 1994-04-25 NO NO941497A patent/NO300976B1/no not_active IP Right Cessation
- 1994-04-29 FI FI942010A patent/FI105548B/sv not_active IP Right Cessation
-
1995
- 1995-04-18 US US08/423,116 patent/US5516908A/en not_active Expired - Lifetime
- 1995-04-18 US US08/423,920 patent/US5541325A/en not_active Expired - Lifetime
-
1996
- 1996-02-07 GR GR960400315T patent/GR3018909T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI105548B (sv) | Förfarande för framställning av farmaceutiskt aktiva 1,3-dihydro-2H-imidazo(4,5-b)kinolin-2-oner | |
FI83316B (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva 1,3-dihydro-2h-imidazo/4,5-b/kinolin-2-onderivat. | |
US5021443A (en) | Noval benzimidazole and azabenzimiazole derivatives which are thromboxane receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present | |
JP4339123B2 (ja) | 5−ヒドロキシトリプタミン−6リガンドとしてのアザインドリルアルキルアミン誘導体 | |
US4954498A (en) | Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use | |
SK22099A3 (en) | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
JP2002542245A (ja) | 置換イミダゾール、それらの製造および使用 | |
JPH06145170A (ja) | ヘテロ環式化合物、その製法及びこれを含有する高血圧及びうつ血性心不全治療用医薬組成物 | |
US5063237A (en) | 1,4-dihydro-2-(4-[benzimidazol-l-yl]phenyl)-pyridines as platelet activating factor antagonists | |
JP3243733B2 (ja) | 新規イソキノリン誘導体 | |
SK12222003A3 (sk) | Beta-karbolínové deriváty, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitia proti depresii a úzkosti | |
JPS59101467A (ja) | 6,7−ジヒドロ−8−(イミダゾ−ル−1−イル)−5−メチル−1−オキソ−1H,5H−ベンゾ〔ij〕キノリジン−2−カルボン酸およびその誘導体 | |
US5026712A (en) | Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents | |
CA1338599C (en) | Imidazole derivatives | |
JPH07242666A (ja) | 複素環化合物 | |
DE69214113T2 (de) | Neue Pyrrolidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
JP2002541145A (ja) | アリールおよびヘテロアリール縮合アミノアルキル−イミダゾール誘導体:ブラジキニンb2受容体選択性モジュレータ | |
US5149814A (en) | Alkyl 2-benzylidene-4-(2-alkylimidazopyrid-1-yl) benzoylacetate esters as intermediate compounds | |
US5070205A (en) | Alkyl 2-benzylidene-4-(benzimidazol-1-yl) benzoylacetate esters as intermediates | |
JP2849123B2 (ja) | 四置換チオフェン及びその製造方法 | |
US5171858A (en) | Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines | |
EP0462986A1 (en) | IMIDAZOPYRIMIDINE ANTIALLERGY AGENTS. | |
JPS6284A (ja) | イミダゾキノリン抗血栓性強心薬 | |
NO893611L (no) | Fremstilling av imidazokinolinonderivater. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MA | Patent expired |